Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12399071 | 0.88 | ALDH1A1 (0.56) | KDM4ETSHRMEN1KMT2ARAB9A | |
| SCHEMBL9355979 | 0.85 | TSHR (0.55) | KDM4ETSHRMEN1KMT2AATM | |
| SCHEMBL16828808 | 0.84 | MEN1 (0.55) | KDM4ETSHRMEN1KMT2ARAB9A | |
| SCHEMBL1017506 | 0.84 | KDM4E (0.55) | KDM4ETSHRRAB9ANPC1CASP3 | |
| SCHEMBL9308330 | 0.84 | TSHR (0.53) | KDM4ETSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL7354531 | 0.84 | TSHR (0.53) | KDM4ETSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL4192112 | 0.84 | CYP1A2 (0.62) | KDM4ETSHRRAB9ANPC1CASP3 | |
| SCHEMBL510572 | 0.82 | ALDH1A1 (0.54) | KDM4ETSHRMEN1KMT2ARAB9A | |
| SCHEMBL2355409 | 0.82 | KDM4E (0.54) | KDM4ETSHRMEN1KMT2ARAB9A | |
| SCHEMBL15211304 | 0.82 | KDM4E (0.54) | KDM4ETSHRRAB9ANPC1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111566103-B | Aminoimidazopyrazines as kinase inhibitors | 百时美施贵宝公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-2968324-B1 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2968324-B1 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9675593-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9359379-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9353104-B2 | Substituted pyridizinone derivatives as PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353104-B2 | Substituted pyridizinone derivatives as PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2968324-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014150114-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014150114-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014139150-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139150-A1 | SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2014-04-17 | — | — | US | disclosed |
| EP-1482954-A4 | ALPHA-SUBSTITUTED ARYLALKYL PHOSPHONATE DERIVATIVES | ILEX PRODUCTS INC (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050124586-A1 | Alpha-substituted arylalkyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2005-06-09 | — | — | US | disclosed |
| EP-1482954-A2 | ALPHA-SUBSTITUTED ARYLALKYL PHOSPHONATE DERIVATIVES | Ilex Products, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003069302-A2 | ALPHA-SUBSTITUTED ARYLALKYL PHOSPHONATE DERIVATIVES | ILEX PRODUCTS, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | KDM4E 2117/4885TSHR 4018/4885MEN1 4562/4885 |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | KDM4E 2117/4885TSHR 4018/4885MEN1 4562/4885 |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | KDM4E 2117/4885TSHR 4018/4885MEN1 4562/4885 |
| US-20050124586-A1 | Alpha-substituted arylalkyl phosphonate derivatives | APOB, APOL1, LDLR | KDM4E 3736/4885TSHR 3056/4885MEN1 4414/4885 |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | KDM4E 2117/4885TSHR 4018/4885MEN1 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.